Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Wnt modulators in the aqueous humor are associated with outer retinal damage severity in patients with neovascular age-related macular degeneration.

Park KH, Choi AJ, Yoon J, Lim D, Woo SJ, Park SJ, Kim HC, Chung H.

Invest Ophthalmol Vis Sci. 2014 Jul 17;55(9):5522-30. doi: 10.1167/iovs.14-14566.

PMID:
25034605
2.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
3.

Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.

dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.

Am J Ophthalmol. 2012 Jan;153(1):155-61.e2. doi: 10.1016/j.ajo.2011.06.001. Epub 2011 Aug 20.

PMID:
21861975
4.

Increased Levels of Dickkopf 3 in the Aqueous Humor of Patients With Diabetic Macular Edema.

Ji B, Lim D, Kim J, Kim HC, Chung H.

Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2296-304. doi: 10.1167/iovs.15-18771.

PMID:
27127928
5.
6.

Association between foveal microstructure and visual outcome in age-related macular degeneration.

Shin HJ, Chung H, Kim HC.

Retina. 2011 Sep;31(8):1627-36. doi: 10.1097/IAE.0b013e31820d3d01.

PMID:
21606888
7.

Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.

Inoue M, Arakawa A, Yamane S, Kadonosono K.

Retina. 2013 May;33(5):990-7. doi: 10.1097/IAE.0b013e3182755793.

PMID:
23446653
8.

Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection.

Roh MI, Lim SJ, Ahn JM, Lim JB, Kwon OW.

Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):635-40. doi: 10.1007/s00417-009-1254-8. Epub 2009 Dec 9.

PMID:
19997926
9.

Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.

Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.

Ophthalmology. 2012 Oct;119(10):2082-6. doi: 10.1016/j.ophtha.2012.07.041. Epub 2012 Aug 22.

PMID:
22920670
10.

Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.

Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.

Retina. 2009 Apr;29(4):523-9. doi: 10.1097/IAE.0b013e318195cb15.

PMID:
19262441
12.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
13.
14.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
15.

Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration.

Oishi A, Shimozono M, Mandai M, Hata M, Nishida A, Kurimoto Y.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):435-40. doi: 10.1007/s00417-012-2034-4. Epub 2012 May 12.

PMID:
22576370
16.

Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.

Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S.

Am J Ophthalmol. 2013 Nov;156(5):989-993.e2. doi: 10.1016/j.ajo.2013.06.020. Epub 2013 Aug 12.

PMID:
23938122
17.

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.

Cho HJ, Kim CG, Yoo SJ, Cho SW, Lee DW, Kim JW, Lee JH.

Am J Ophthalmol. 2013 Jan;155(1):118-126.e1. doi: 10.1016/j.ajo.2012.07.009. Epub 2012 Sep 27.

PMID:
23022163
18.

Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration.

Fauser S, Schwabecker V, Muether PS.

Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28.

PMID:
24879948
20.

The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.

Aslankurt M, Aslan L, Aksoy A, Erden B, Cekiç O.

Eur J Ophthalmol. 2013 Jul-Aug;23(4):553-7. doi: 10.5301/ejo.5000268. Epub 2013 Mar 20.

Supplemental Content

Support Center